XYou may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com.
XYou may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com.
This report describes the successful treatment of 4 adult men who presented with concerns about problematic sexual interests and behaviors that began after treatment with pramipexole related to Parkinson’s disease or restless leg syndrome.
About 10% of patients diagnosed with OCD remain symptomatic despite standard pharmaceutical and psychotherapy treatments. This brief report discusses the possible role of transcranial magnetic stimulation in the treatment of these patients.
Women seem more likely than men to develop obsessive-compulsive disorder (OCD), but findings of individual studies are inconsistent. This meta-analysis estimated the worldwide prevalence of OCD to determine if the disorder is indeed more common in women.
This case series includes 3 patients diagnosed with papillary thyroid carcinoma who also had subthreshold obsessive-compulsive symptoms. Read on to find out about the diagnostic process and course of treatment.
How common is self-harm among women during the perinatal period, and what factors are associated with self-harm in this population? This systematic review aims to answer these questions.
dos Santos-Ribeiro and colleagues reply to the letter "Electroconvulsive Therapy Is Helpful for Patients With Obsessive-Compulsive Disorder-Related Disorders" by Kellner et al.
In this letter to the editor, Dr Kellner and colleagues comment on the article "A Systematic Review of the Utility of Electroconvulsive Therapy in Broadly Defined Obsessive-Compulsive-Related Disorders" by dos Santos-Ribeiro et al.
Developmental vulnerability for mental disorders exists in childhood and adolescence. Read this article to learn the incidences and risk factors of mental disorders across childhood and adolescence in a nationwide birth cohort.
Here, read about a 44-year-old woman with diagnoses of OCD and body dysmorphic disorder who presented for evaluation of depression with suicidal thinking. The case illustrates a multipronged approach that included addressing the patient's depressive symptoms, cotreating with a psychologist, and prescribing medication.Â
Psychogenic movement disorders (PMDs) are common and frequently comorbid with other physical and psychiatric conditions. However, treatment of PMDs has been largely unsuccessful. This report describes a patient initially diagnosed with a PMD, who later received a diagnosis of comorbid OCD. Treatment with exposure and response prevention, an evidence-based psychotherapy for OCD, was successful in treating both conditions. Read on to find out more.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”